2020
Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis
Marx FM, Cohen T, Menzies NA, Salomon JA, Theron G, Yaesoubi R. Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis. The Lancet Global Health 2020, 8: e1223-e1233. PMID: 32827484, PMCID: PMC7549318, DOI: 10.1016/s2214-109x(20)30227-8.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapySecondary preventive therapyHigh-incidence settingsPost-treatment followPreventive therapyTuberculosis controlTuberculosis incidenceTreatment completionTuberculosis case findingOverall disease burdenHigh tuberculosis incidenceTuberculosis-endemic settingHigh-incidence communityFirst yearHealth system costsRecurrent tuberculosisSecondary preventionAnnual followTuberculosis treatmentDisease burdenHigh riskCase findingSingle followSuburban Cape TownPreventive interventions
2019
Notification of relapse and other previously treated tuberculosis in the 52 health districts of South Africa
Marx F, Cohen T, Lombard C, Hesseling A, Dlamini S, Beyers N, Naidoo P. Notification of relapse and other previously treated tuberculosis in the 52 health districts of South Africa. The International Journal Of Tuberculosis And Lung Disease 2019, 23: 891-899. PMID: 31533878, DOI: 10.5588/ijtld.18.0609.Peer-Reviewed Original ResearchConceptsSouth African health districtTB casesCase notification ratesHealth districtTB burdenNotification ratesHigh case notification ratesHIV co-infection rateHuman immunodeficiency virus (HIV) prevalenceTB case notification ratesAntenatal HIV prevalenceSecondary preventive therapyDrug-susceptible tuberculosisNew TB casesCo-infection rateTreatment history informationPreventive therapyMultivariable analysisHIV prevalenceSouth African districtPatient categoriesRelapseTuberculosisTreatment monitoringVirus prevalence